GoodRx (GDRX)
(Delayed Data from NSDQ)
$6.88 USD
-0.18 (-2.55%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.89 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.88 USD
-0.18 (-2.55%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.89 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
NextGen Healthcare (NXGN) Q2 Earnings Beat, FY23 View Up
by Zacks Equity Research
NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.
Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.
Here's Why GoodRx Holdings, Inc. (GDRX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
MD or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. GDRX: Which Stock Is the Better Value Option?
ELV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 50% and 4.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of -2.04% and 2.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: GoodRx Holdings, Inc. (GDRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings?
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.
AMN Healthcare (AMN) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) second-quarter results are likely to reflect solid demand across all its segments.
NextGen Healthcare (NXGN) Beats on Q1 Earnings, Cuts FY23 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) first-quarter fiscal 2023 results reflect strength in its Recurring revenues.
Neogen (NEOG) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) delivers better-than-expected results for the fiscal fourth quarter, with robust segmental performance driving the top line.
ELV vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
GoodRx Holdings, Inc. (GDRX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 25% and 1.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AMN vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
AMN Healthcare Services (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 7.38% and 3.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Refresh Your Portfolio by Dumping These 5 Toxic Stocks
by Rimmi Singhi
Get rid of toxic stocks like GoodRx (GDRX), Insulet (PODD), Vonage (VG), AppLovin (APP) and Embraer (ERJ) to avoid portfolio bleeding.
AMN vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Zacks.com featured highlights include Atlantica Yield, Astronics, GoodRx Holdings, and Las Vegas Sands
by Zacks Equity Research
Atlantica Yield, Astronics, GoodRx Holdings, and Las Vegas Sands are part of the Screen of the Week article.
Beware of These 4 Toxic Stocks Amid Market Uncertainty
by Rimmi Singhi
Safeguard your portfolio by dumping these toxic stocks- Atlantica Yield (AY), Astronics (ATRO), GoodRx (GDRX) and Las Vegas Sands (LVS).